Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.